



















Anticipated Upcoming Data for Gilead's Investigational Drug for COVID-19

DATA SOURCE		NUMBER OF PATIENTS	APRIL	MAY	JUNE
 GILEAD Compassionate Use Initial Data Subset		 53 CRITICAL SEVERE	 April 10		
	 Double-Blind Placebo-Controlled	 TBD SEVERE		Discontinued Due to Low Enrollment; Data TBD	
Simple Studies	 GILEAD Open-Label Severe	 400+ EXPANSION TO ADD CRITICAL AND SEVERE PATIENTS SEVERE	 Late April		
	 GILEAD Open-Label Moderate	 600+ EXPANSION TO ADD MODERATE PATIENTS MODERATE		 Late May	
 NIH NIAID Double-Blind Placebo-Controlled	 800+ CRITICAL SEVERE MODERATE		 Late May		
Other Trials	  	 10,000+ CRITICAL SEVERE MODERATE			After June

 **Critical**
 Intubated

 **Severe**
 Requiring Oxygen

 **Moderate**
 Hospitalized Patients

The dates of publication are subject to change and are estimates based on limited information.